|
Dr. Bruce Sargent joined Albany Molecular Research in 2001, bringing over 20 years of drug discovery experience from Boots Pharmaceuticals in the UK (latterly Knoll Ltd., the UK division of BASF Pharma). Dr. Sargent rose through the ranks to become head of chemistry at Knoll. While there, he managed research projects in several therapeutic areas, with a particular focus on CNS and metabolic diseases. During his career, Dr. Sargent and his team delivered twelve compounds into advanced preclinical testing, nine of which reached Phase I human clinical testing. In particular, Dr. Sargent was closely involved with the discovery and development of the anti-obesity agent sibutramine (Meridia�/Reductil�). In addition to scientific and departmental management responsibilities, Dr. Sargent had strategic involvement in portfolio, licensing, M&A and collaborative activities. Dr. Sargent also led efforts in restructuring and refocusing Knoll�s chemistry department. Dr. Sargent�s involvement at Knoll was international, managing groups in Spain and India and collaborating extensively with groups in Germany and the USA.
Since joining Albany Molecular Research, Dr. Sargent has held responsibility for several customer relationships in medicinal chemistry, covering a wide range of therapeutic approaches. His current responsibilities also embrace bioscience, in vitro biology and natural product operations. He is a member of the American Chemical Society and a Fellow of the Royal Society of Chemistry. He obtained his B.A. and M.A. degrees from the University of Cambridge and his Ph.D. from the University of Manchester. Dr. Sargent has received multiple patents as well as over ten publications and five presentations. | 